Bell Potter keeps AUD 4.40 target for Mesoblast stock after USD 28.00 million sales
Published on 10/27/2026 at 18:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and sales update
- Bell Potter retained a Buy rating and an AUD 4.40 target in October 2026.
- Ryoncil sales reached USD 28.00 million against a USD 40.00 million forecast for the September 2026 quarter.
- Mesoblast stock cost EUR 1.18 at Lang & Schwarz on October 27, 2026.
- Nasdaq trading put Mesoblast's market capitalization at USD 1.7 billion on October 27, 2026.
Mesoblast (AU000000MSB8) posted USD 28.00 million in Ryoncil sales for the September 2026 quarter, below the USD 40.00 million forecast cited by The Motley Fool Australia on October 19, 2026. Bell Potter retained its Buy rating and an AUD 4.40 price target, while Mesoblast stock cost EUR 1.18 at Lang & Schwarz on October 27, 2026.
Sales growth meets a forecast gap
The September quarter figure gives investors a sharper operating marker than the headline revenue growth alone. The USD 28.00 million Ryoncil result reached 70.00 percent of the USD 40.00 million forecast, leaving a USD 12.00 million shortfall.
The same report said Bell Potter reduced its fiscal 2027 Ryoncil revenue forecast by 18.00 percent, from USD 243.00 million to USD 203.00 million, and lowered its fiscal 2027 net profit after tax forecast to USD 26.70 million. The broker also cut its fiscal 2028 revenue forecast by 7.00 percent, while retaining its positive rating, according to The Motley Fool Australia.
Nasdaq range keeps the risk visible
On the Nasdaq, Mesoblast stock last traded at USD 13.12 on October 27, 2026 at 1:55 p.m. ET. Its 52-week range was USD 11.89 to USD 21.50, placing the latest quote USD 1.23 above the low and USD 8.38 below the high.
The US listing carried a market capitalization of USD 1.7 billion on October 27, 2026. That valuation sits alongside the sharply revised fiscal 2027 forecast, making Ryoncil sales conversion the key operating measure in the latest broker view.
What does the target imply?
Bell Potter's AUD 4.40 target was stated in a report released in October 2026, while the broker's forecast revisions reflected the September quarter sales gap. The report linked the lower fiscal 2027 estimate to the USD 28.00 million Ryoncil result, but retained the Buy rating.
Stock price and investor context
Mesoblast stock was trading at EUR 1.18 at Lang & Schwarz on October 27, 2026 at 6:50 p.m. CEST. The Nasdaq quote was USD 13.12 on October 27, 2026 at 1:55 p.m. ET, while the latest company update covered the September 2026 quarter.
The further course of trading is shown by the continuously updated real-time quote of Mesoblast stock.
Mesoblast at a glance
- Company: Mesoblast Limited
- ISIN: AU000000MSB8
- Ticker: MESO
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 27, 2026, 6:50 p.m. CEST): EUR 1.18
- Market capitalization: USD 1.7 billion (as of October 27, 2026)
- 52-week range: USD 11.89-21.50 (as of October 27, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: S&P 500
Market context: Market report S&P 500.
